1-17 of 17
Gini F. Fleming
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors

Pamela N. Munster, Andrew E. Greenstein, Gini F. Fleming, Erkut Borazanci, Manish R. Sharma, Joseph M. Custodio, Iulia Cristina Tudor, Hristina I. Pashova, Stacie Peacock Shepherd, Andreas Grauer, Jasgit C. Sachdev
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (15): 3214–3224.
https://doi.org/10.1158/1078-0432.CCR-21-4363
Published: 02 August 2022
View article titled, Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors
Open the PDF for Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors

Corey C. Foster, Gini F. Fleming, Theodore G. Karrison, Chih-Yi Liao, Ami V. Desai, John W. Moroney, Mark J. Ratain, Rita Nanda, Blase N. Polite, Olwen M. Hahn, Peter H. O'Donnell, Everett E. Vokes, Hedy L. Kindler, Robyn Hseu, Linda A. Janisch, Julia Dai, Mark D. Hoffman, Ralph R. Weichselbaum, Sean P. Pitroda, Steven J. Chmura, Jason J. Luke
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (20): 5510–5518.
https://doi.org/10.1158/1078-0432.CCR-21-0810
Published: 15 October 2021
View article titled, Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors
Open the PDF for Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial

Jason J. Luke, Benjamin E. Onderdonk, Sandeep R. Bhave, Theodore Karrison, Jeffrey M. Lemons, Paul Chang, Yuanyuan Zha, Tim Carll, Thomas Krausz, Lei Huang, Carlos Martinez, Linda A. Janisch, Robyn D. Hseu, John W. Moroney, Jyoti D. Patel, Nikolai N. Khodarev, Joseph K. Salama, Patrick A. Ott, Gini F. Fleming, Thomas F. Gajewski, Ralph R. Weichselbaum, Sean P. Pitroda, Steven J. Chmura
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (24): 6437–6444.
https://doi.org/10.1158/1078-0432.CCR-20-1790
Published: 15 December 2020
View article titled, Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial
Open the PDF for Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial in another window
Includes: Supplementary data
Journal Articles

Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86)

Neesha C. Dhani, Hal W. Hirte, Lisa Wang, Julia V. Burnier, Angela Jain, Marcus O. Butler, Stephen Welch, Gini F. Fleming, Jean Hurteau, Koji Matsuo, Daniela Matei, Waldo Jimenez, Carolyn Johnston, Mihaela Cristea, Katia Tonkin, Prafull Ghatage, Stephanie Lheureux, Anjali Mehta, Judy Quintos, Qian Tan, Suzanne Kamel-Reid, Olga Ludkovski, Ming-Sound Tsao, John J. Wright, Amit M. Oza
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (11): 2477–2486.
https://doi.org/10.1158/1078-0432.CCR-19-2576
Published: 01 June 2020
View article titled, Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86)
Open the PDF for Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86) in another window
Includes: Supplementary data
Journal Articles

A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer

Amit M. Oza, Ursula A. Matulonis, Angeles Alvarez Secord, John Nemunaitis, Lynda D. Roman, Sarah P. Blagden, Susana Banerjee, William P. McGuire, Sharad Ghamande, Michael J. Birrer, Gini F. Fleming, Merry Jennifer Markham, Hal W. Hirte, Diane M. Provencher, Bristi Basu, Rebecca Kristeleit, Deborah K. Armstrong, Benjamin Schwartz, Patricia Braly, Geoff D. Hall, Kenneth P. Nephew, Simone Jueliger, Aram Oganesian, Sue Naim, Yong Hao, Harold Keer, Mohammad Azab, Daniela Matei
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (5): 1009–1016.
https://doi.org/10.1158/1078-0432.CCR-19-1638
Published: 02 March 2020
View article titled, A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer
Open the PDF for A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor–Engineered T Cells for Ovarian Cancer

Tatsuo Matsuda, Matthias Leisegang, Jae-Hyun Park, Lili Ren, Taigo Kato, Yuji Ikeda, Makiko Harada, Kazuma Kiyotani, Ernst Lengyel, Gini F. Fleming, Yusuke Nakamura
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (21): 5357–5367.
https://doi.org/10.1158/1078-0432.CCR-18-0142
Published: 01 November 2018
View article titled, Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor–Engineered T Cells for Ovarian Cancer
Open the PDF for Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor–Engineered T Cells for Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer

Diana C. West, Masha Kocherginsky, Eva Y. Tonsing-Carter, D. Nesli Dolcen, David J. Hosfield, Ricardo R. Lastra, Jason P. Sinnwell, Kevin J. Thompson, Kathleen R. Bowie, Ryan V. Harkless, Maxwell N. Skor, Charles F. Pierce, Sarah C. Styke, Caroline R. Kim, Larischa de Wet, Geoffrey L. Greene, Judy C. Boughey, Matthew P. Goetz, Krishna R. Kalari, Liewei Wang, Gini F. Fleming, Balázs Györffy, Suzanne D. Conzen
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (14): 3433–3446.
https://doi.org/10.1158/1078-0432.CCR-17-2793
Published: 15 July 2018
View article titled, Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer
Open the PDF for Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses

Daniela Matei, Sharad Ghamande, Lynda Roman, Angeles Alvarez Secord, John Nemunaitis, Merry Jennifer Markham, Kenneth P. Nephew, Simone Jueliger, Aram Oganesian, Sue Naim, Xiang Yao Su, Harold Keer, Mohammad Azab, Gini F. Fleming
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (10): 2285–2293.
https://doi.org/10.1158/1078-0432.CCR-17-3055
Published: 14 May 2018
View article titled, A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses
Open the PDF for A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses in another window
Includes: Supplementary data
Journal Articles

Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide

Peter H. O'Donnell, Sanja Karovic, Theodore G. Karrison, Linda Janisch, Matthew R. Levine, Pamela J. Harris, Blase N. Polite, Ezra E.W. Cohen, Gini F. Fleming, Mark J. Ratain, Michael L. Maitland
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (22): 5092–5099.
https://doi.org/10.1158/1078-0432.CCR-15-0427
Published: 12 November 2015
View article titled, Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide
Open the PDF for Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide in another window
Includes: Supplementary data
Journal Articles

Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer

Shivaani Kummar, Amit M. Oza, Gini F. Fleming, Daniel M. Sullivan, David R. Gandara, Michael J. Naughton, Miguel A. Villalona-Calero, Robert J. Morgan, Jr, Peter M. Szabo, Ahrim Youn, Alice P. Chen, Jiuping Ji, Deborah E. Allen, Chih-Jian Lih, Michele G. Mehaffey, William D. Walsh, Paul M. McGregor, III, Seth M. Steinberg, P. Mickey Williams, Robert J. Kinders, Barbara A. Conley, Richard M. Simon, James H. Doroshow
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (7): 1574–1582.
https://doi.org/10.1158/1078-0432.CCR-14-2565
Published: 31 March 2015
View article titled, Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or <em>BRCA</em>-Mutant Ovarian Cancer
Open the PDF for Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or <em>BRCA</em>-Mutant Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract B32: The role of the glucocorticoid receptor (GR) in inhibiting chemotherapy-induced apoptosis in high-grade serous ovarian carcinoma (HGS-OvCa)

Erica M. Stringer, Maxell N. Skor, Lei Zhao, Katja Gwin, Ernst Lengyel, Gini F. Fleming, Suzanne D. Conzen
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (19_Supplement): B32.
https://doi.org/10.1158/1078-0432.OVCA13-B32
Published: 13 May 2014
View article titled, Abstract B32: The role of the glucocorticoid receptor (GR) in inhibiting chemotherapy-induced apoptosis in high-grade serous ovarian carcinoma (HGS-OvCa)
Journal Articles

Phase I Studies of Sirolimus Alone or in Combination with Pharmacokinetic Modulators in Advanced Cancer Patients

Ezra E.W. Cohen, Kehua Wu, Christine Hartford, Masha Kocherginsky, Kimberly Napoli Eaton, Yuanyuan Zha, Anitha Nallari, Michael L. Maitland, Kammi Fox-Kay, Kristin Moshier, Larry House, Jacqueline Ramirez, Samir D. Undevia, Gini F. Fleming, Thomas F. Gajewski, Mark J. Ratain
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (17): 4785–4793.
https://doi.org/10.1158/1078-0432.CCR-12-0110
Published: 30 August 2012
View article titled, Phase I Studies of Sirolimus Alone or in Combination with Pharmacokinetic Modulators in Advanced Cancer Patients
Open the PDF for Phase I Studies of Sirolimus Alone or in Combination with Pharmacokinetic Modulators in Advanced Cancer Patients in another window
Includes: Supplementary data
Journal Articles

Two Drug Interaction Studies of Sirolimus in Combination with Sorafenib or Sunitinib in Patients with Advanced Malignancies

Tara C. Gangadhar, Ezra E.W. Cohen, Kehua Wu, Linda Janisch, David Geary, Masha Kocherginsky, Larry K. House, Jackie Ramirez, Samir D. Undevia, Michael L. Maitland, Gini F. Fleming, Mark J. Ratain
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (7): 1956–1963.
https://doi.org/10.1158/1078-0432.CCR-10-2061
Published: 31 March 2011
View article titled, Two Drug Interaction Studies of Sirolimus in Combination with Sorafenib or Sunitinib in Patients with Advanced Malignancies
Open the PDF for Two Drug Interaction Studies of Sirolimus in Combination with Sorafenib or Sunitinib in Patients with Advanced Malignancies in another window
Journal Articles

Administration of Glucocorticoids to Ovarian Cancer Patients Is Associated with Expression of the Anti-apoptotic Genes SGK1 and MKP1/DUSP1 in Ovarian Tissues

Amal Melhem, S. Diane Yamada, Gini F. Fleming, Bertha Delgado, Deanna R. Brickley, Wei Wu, Masha Kocherginsky, Suzanne D. Conzen
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (9): 3196–3204.
https://doi.org/10.1158/1078-0432.CCR-08-2131
Published: 30 April 2009
View article titled, Administration of Glucocorticoids to Ovarian Cancer Patients Is Associated with Expression of the Anti-apoptotic Genes <em>SGK1</em> and <em>MKP1/DUSP1</em> in Ovarian Tissues
Open the PDF for Administration of Glucocorticoids to Ovarian Cancer Patients Is Associated with Expression of the Anti-apoptotic Genes <em>SGK1</em> and <em>MKP1/DUSP1</em> in Ovarian Tissues in another window
Includes: Supplementary data
Journal Articles

A Phase I Trial of Escalating Doses of Trastuzumab Combined with Daily Subcutaneous Interleukin 2: Report of Cancer and Leukemia Group B 9661

Gini F. Fleming, Neal J. Meropol, Gary L. Rosner, Donna R. Hollis, William E. Carson, III, Michael Caligiuri, Joanne Mortimer, Katherine Tkaczuk, Robin Parihar, Richard L. Schilsky, Mark J. Ratain
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (12): 3718–3727.
Published: 01 December 2002
View article titled, A Phase I Trial of Escalating Doses of Trastuzumab Combined with Daily Subcutaneous Interleukin 2: <subtitle>Report of Cancer and Leukemia Group B 9661</subtitle>
Open the PDF for A Phase I Trial of Escalating Doses of Trastuzumab Combined with Daily Subcutaneous Interleukin 2: <subtitle>Report of Cancer and Leukemia Group B 9661</subtitle> in another window
Journal Articles

Phase I Trial of ISIS 5132, an Antisense Oligonucleotide Inhibitor of c-raf-1, Administered by 24-hour Weekly Infusion to Patients with Advanced Cancer

Charles M. Rudin, Jon Holmlund, Gini F. Fleming, Sridhar Mani, Walter M. Stadler, Philip Schumm, Brett P. Monia, Joseph F. Johnston, Richard Geary, Rosie Z. Yu, T. Jesse Kwoh, F. Andrew Dorr, Mark J. Ratain
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (5): 1214–1220.
Published: 01 May 2001
View article titled, Phase I Trial of ISIS 5132, an Antisense Oligonucleotide Inhibitor of c-<em>raf</em>-1, Administered by 24-hour Weekly Infusion to Patients with Advanced Cancer
Open the PDF for Phase I Trial of ISIS 5132, an Antisense Oligonucleotide Inhibitor of c-<em>raf</em>-1, Administered by 24-hour Weekly Infusion to Patients with Advanced Cancer in another window
Journal Articles

Human Breast Cancer Susceptibility to Paclitaxel Therapy Is Independent of Bcl-2 Expression

Susan M. Poelman, Moses O. Adeyanju, Maria-Antonia Robertson, Wendy M. Recant, Theodore Karrison, Gini F. Fleming, Olufunmilayo I. Olopade, Suzanne D. Conzen
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (10): 4043–4048.
Published: 01 October 2000
View article titled, Human Breast Cancer Susceptibility to Paclitaxel Therapy Is Independent of Bcl-2 Expression
Open the PDF for Human Breast Cancer Susceptibility to Paclitaxel Therapy Is Independent of Bcl-2 Expression in another window